Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Results after the implantation of the Scharioth macula lens in patients with age-related macular degeneration: 12 month follow-up

Search Title by author or title

Session Details

Session Title: Glaucoma & Posterior Segment

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 09:48

Venue: Room A3, Podium 1

First Author: : G.Harb LEBANON

Co Author(s): :    W. Harb                    

Abstract Details


To report visual outcomes and improvement after the implantation of the Scharioth Macula Lens (Medicontur, Hungary), an add-on type intraocular implant that was designed to improve the near vision of pseudophakic patients suffering from the non-exudative forms of macular degeneration.


Levant HOSPITAL, Beirut, Lebanon


Monocularly a lens was implanted with special, +10D central addition in the sulcus of the better-seeing eye of 8 pseudophakic patients. All patients have the dry form of AMD. The preoperative CNVA were tested at 40 cm with a +2.5D addition, and then at 15 cm with a +6.0D addition to predict the prospective improvement in vision. All implanted patients had shown at least 2 lines of improvement in the preliminary testing. We tested both the corrected and uncorrected near and distance visual acuities of patients 1 day, 1 week, 1,3,6,12 months after surgery. The distance vision was also assessed.


There were no intra/postoperative complications in any of the patients. The preoperative CNVAs with +2.5D and +6.0D addition were 0.20±0.08 and 0.41±0.13, respectively. The uncorrected near vision at 15 cm improved to 0.46±0.18 at twelve months postoperatively. The predicted near vision improvement was 3 lines. Far vision was not affected by the implant: the uncorrected distance vision (UCDVA) was 0.07±0.02 preoperatively and 0.08±0.04 at the follow-up visits after the operation. The corrected distance visual acuity (BCDVA) was 0.11±0.06 before and 0.09±0.05 after the implantation.


The special add-on SML implant is a safe and effective device that helps improving the near vision of patients with the dry AMD. The eligible patients had their CNVA measured with a +2.5D and a +6.0D addition, which proved to be a reliable preliminary testing method. Postoperative CNVA confirm that there was significant improvement in near vision for all patients, even 1 year after the surgery. Both the corrected and the uncorrected far visual acuities were unaffected by the SML. The SML implantation is a promising method for enhancing the quality of life of patients who suffer from non-exudative AMD.

Financial Disclosure:


Back to previous